Solara Active Pharma Sciences Ltd (SOLARA) Q2FY27 Management Mirror - Sep-2026 Qtr
Ibuprofen Strategic Review Deferred to Q3 FY27; Loss Guidance Exceeded as Segment Nears Breakeven
In Sep'26 Qtr concall commentary, the ibuprofen business operated close to breakeven on 91 crores revenue, while management updated that the strategic review of the business and Vizag facility is ongoing. This operating performance exceeded the quarterly EBITDA loss of 10 crores to 15 crores guided in the Jun'26 Qtr concall, whereas the strategic review timeline was deferred from the H1 FY27 conclusion initially guided in the Mar'26 Qtr and reaffirmed in the Jun'26 Qtr. Management now expects the review to conclude in an estimated 12 weeks, evaluating options including repurposing the single-product Vizag facility into a multi-product captive site or pursuing an external divestment.
4 more themes on the ELITE plan.